Celldex Therapeutics Inc. (NASDAQ:CLDX)’s share price dropped 3.4% on Thursday . The stock traded as low as $4.49 and last traded at $4.50, with a volume of 1,030,063 shares. The stock had previously closed at $4.66.

CLDX has been the topic of several recent research reports. Roth Capital reiterated a “buy” rating and issued a $7.00 price objective on shares of Celldex Therapeutics in a research note on Tuesday, April 19th. Cowen and Company restated an “outperform” rating and set a $12.00 target price on shares of Celldex Therapeutics in a research note on Tuesday, April 19th. Jefferies Group restated a “hold” rating and set a $4.00 target price on shares of Celldex Therapeutics in a research note on Friday, May 6th. Finally, Wedbush restated a “neutral” rating and set a $3.00 target price on shares of Celldex Therapeutics in a research note on Friday, May 6th. Six analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. Celldex Therapeutics currently has an average rating of “Hold” and a consensus price target of $14.11.

The stock’s 50 day moving average price is $4.55 and its 200 day moving average price is $5.12. The company’s market capitalization is $445.22 million.

Celldex Therapeutics (NASDAQ:CLDX) last issued its quarterly earnings results on Thursday, May 5th. The biopharmaceutical company reported ($0.35) earnings per share for the quarter, hitting the Zacks’ consensus estimate of ($0.35). During the same quarter in the previous year, the firm posted ($0.33) EPS. The business had revenue of $1.30 million for the quarter, compared to analysts’ expectations of $1.06 million. Celldex Therapeutics’s revenue was up 160.0% on a year-over-year basis. On average, equities research analysts anticipate that Celldex Therapeutics Inc. will post ($1.36) earnings per share for the current year.

An institutional investor recently raised its position in Celldex Therapeutics stock. Rhumbline Advisers boosted its position in shares of Celldex Therapeutics Inc. (NASDAQ:CLDX) by 4.9% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 108,426 shares of the biopharmaceutical company’s stock after buying an additional 5,110 shares during the period. Rhumbline Advisers owned approximately 0.11% of Celldex Therapeutics worth $1,700,000 as of its most recent SEC filing.

Celldex Therapeutics, Inc is a biopharmaceutical company focused on the development and commercialization of several immunotherapy technologies for the treatment of cancer and other difficult-to-treat diseases. The Company is engaged in the development of targeted immunotherapeutics comprised of antibodies, adjuvants and monotherapies and antibody-drug conjugates that treat cancers and other diseases.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.